Exonics Therapeutics Stock

exonicstx.comHealthcareFounded: 2017Funding to Date: $45MM

Developer of gene repair therapies designed for devastating genetic neuromuscular diseases. The company's uses CRISPR/Cas9 technology which is a potential one-time treatment that would make a permanent correction of the mutation that causes Duchenne by identifying and correcting exon mutations that prevent the production of dystrophin, a protein that helps stabilize and protect muscle fibers, enabling patients to improve their lives and have a lifelong benefit.

Register for Details

For more details on financing and valuation for Exonics Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Exonics Therapeutics.

Register Today

Team

Management Team

John Ripple
Chief Executive Officer & Board Member
David Goeddel Ph.D
Chairman
Jesper Gromada Ph.D
Chief Scientific Officer
Eric Olson Ph.D
Founder, Chief Science Advisor & Board Observer

Board Members

John Edwards
Eric Olson Ph.D
David Goeddel Ph.D
JeenJoo Kang Ph.D
The Column Group
John Ripple

Other companies like Exonics Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM
Sector
Last Round Est. Valuation
$4.8B

News

Exonics Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company, secured $40m in Series A financing. The Column Group (TCG), a science-driven venture capital firm, made the investment. In conjunction with the funding, TCG’s David Goeddel, Ph.D., managing partner, and JJ Kang, Ph.D., principal, will be joining the company’s board of directors. The company intends to use …